A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
MET as a Target in Papillary Renal Cell Carcinoma
2014
Clinical Cancer Research
Preserved Fulltext
The biology underlying papillary renal cell carcinoma (RCC) is largely unknown and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in both types 1 and 2 papillary RCC (pRCC) may help to select patients who are more likely to benefit from MET inhibitors.
doi:10.1158/1078-0432.ccr-14-0690
pmid:24812413
fatcat:tsnc4lagbnhefdolmr5yjgahzu